Highlighting the importance of the treatment schedule, recent data revealed that GAS6 and AXL significantly increased in plasma of COVID-19 patients as compared to controls, while GAS6 decreased over time in patients surviving to 30 days post ICU admission. The gene discussed is GAS6; the disease is COVID-19.